Dust mite component Analysis: Identifying key allergens components for effective immunotherapy in allergic rhinitis

Area of Science:

• Immunology
• Allergology
• Biomarkers

Background:

• House dust mite (HDM) sensitization is common in allergic rhinitis.
• Subcutaneous immunotherapy (SCIT) is a treatment option for allergic rhinitis.
• Understanding sensitization profiles can optimize SCIT efficacy.

Purpose of the Study:

• To determine the frequency of sensitization to HDM components in allergic rhinitis patients receiving SCIT.
• To evaluate the relationship between SCIT effectiveness and specific IgE (sIgE) levels against HDM allergens.
• To identify potential biomarkers for monitoring SCIT treatment outcomes.

Main Methods:

• Collected serum samples and clinical data from 38 allergic rhinitis patients undergoing HDM-SCIT.
• Measured sIgE levels for specific HDM components (Der f, Der p 1, Der p 2, Der p 10, Der p 23) using fluoroenzymeimmunoassay.
• Analyzed cytokine levels (IL-2, IL-4, IL-6) and EOS% via ELISA and correlated with clinical efficacy (Therapeutic Index >50%).

Main Results:

• High sensitization rates observed for major HDM allergens (Der p, Der f, Der p 1, Der p 2).
• Patients responding to SCIT had higher baseline IgE levels for HDM components, particularly Der p 1.
• Effective SCIT correlated with decreased sIgE levels and reduced IL-2, IL-4, IL-6, and EOS%, while ineffective treatment showed opposite trends.

Conclusions:

• Molecular sensitization profiles in HDM-SCIT are diverse and linked to treatment success.
• Molecular diagnostics can help select appropriate candidates for HDM-SCIT, improving clinical outcomes.
• Serum cytokine levels (IL-2, IL-4, IL-6) and EOS% show promise as biomarkers for monitoring HDM-SCIT efficacy.